杨宁介入医学网

2013.01.22 生物可吸收性药物洗脱金属支架 文章类型: Primary 来自 The Lancet. 2013;doi:10.1016/S0140-6736(12)61765-6. 研究显示了可行性和良好的安全性 背景 人们开发生物可吸收性血管支架旨在克服永久性金属裸支架或药物洗脱冠状动脉支架的局限性，即：...

美国FDA批准拜瑞妥的临床应用适应症的扩大 11月2日，美国食品和药物管理局（FDA）批准扩大利伐沙班（拜瑞妥）适应症，包括治疗下肢深静脉血栓形成（DVT）或肺栓塞（PE），以减少初始治疗后复发性DVT和PE的风险。 在2011年7月美国食品和药物管理局已经批准利...

Symplicity HTN-2 肾去交感神经支配术 6个月随访显示治疗后血压显著下降，没有肾脏损伤的证据 第一个病人入组Symplicity HTN-3 加拿大接受去肾交感神经支配系统执照申请 Symplicity HTN-2 的评论文章...

First US peripheral artery disease patient enrolled in CONNECT II trial Tuesday, 13 Mar 2012 09:43 Ocelot Avinger has announced the enrolment of the first US patient in the multicentre, non-randomised CONNECT II global clinical trial desig...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

Colon Cancer Survival Improved With Use Of Oxaliplatin In 2011, about 101,340 Americans have been diagnosed with colon cancer, a leading worldwide cause of both illness and death, with around one third of cancers being diagnosed as stage I...

拜耳介入专家委员会在三亚召开 一年一度的拜耳介入专家委员会近日在三亚召开。与会的数十名来自全国的介入放射学领域的专家就下列议题进行了热烈的讨论。 （1）TACE联合索拉菲尼治疗肝癌的研究进展（中山大学附属第一医院 杨建勇） （2）肝癌治疗现状中国与...

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Long-Term Outcome of Transcatheter Subsegmental and Segmental Arterial Chemoemobolization Using Lipiodol for Hepatocellular Carcinoma . Percutane...

靶向肿瘤治疗的病人因素 难治性脑动脉瘤新装置PED，获FDA批准（下图）...